{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:54:11Z","timestamp":1772632451582,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasiform eruption is an uncommon cutaneous immune-related adverse event (irAE) associated with anti-PD-1 therapy, and its rapid recurrence upon switching to a different anti-PD-1 agent is a scarcely documented phenomenon. We report the case of a 59-year-old man with stage IIB lung adenocarcinoma who developed a pruritic, scaly eruption after his fourth cycle of pembrolizumab. Histopathological examination confirmed a diagnosis of grade 2 psoriasiform dermatitis according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The initial episode was resolved with systemic corticosteroids. However, upon switching anti-PD-1 therapy to tislelizumab, a similar but more widespread eruption recurred rapidly within a week. The recurrence was successfully managed with topical corticosteroid and antihistamines, and the anti-PD-1 therapy was subsequently discontinued. During the 3-year follow-up after discontinuation, the patient\u2019s skin lesions resolved completely with no recurrence, and no tumor progression was observed. The reduced latency of psoriasiform dermatitis recurrence upon anti-PD-1 inhibitor rechallenge suggests a memory T cell\u2013driven immune response. It also highlights that such irAEs were observed with the two PD-1 inhibitors pembrolizumab and tislelizumab used in this case and can be effectively managed. In this case, tumor progression was not observed after treatment cessation, although causality cannot be inferred.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1760904","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:01:59Z","timestamp":1772607719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Rapid recurrence of psoriasiform dermatitis upon sequential anti-PD-1 therapy with pembrolizumab and tislelizumab with 3-year follow-up"],"prefix":"10.3389","volume":"17","author":[{"given":"Chao-Cheng","family":"Chi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiamen Chang Gung Hospital","place":["Ximan, China"]},{"name":"Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital","place":["Hangzhou, China"]},{"name":"Department of Dermatology, Zhejiang University School of Medicine Affiliated Zhejiang Hospital","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Qing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang-Li","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13150","article-title":"Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern","volume":"45","author":"Trinidad","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e14830","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1684390","article-title":"Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS","volume":"16","author":"Ma","year":"2025","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo UB","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e70815","DOI":"10.7759\/cureus.70815","article-title":"Lymphocytic esophagitis associated with chronic severe psoriasis: A case report with special reference to programmed death-ligand 1 expression","volume":"16","author":"Koleva","year":"2024","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.3390\/ijms22169004","article-title":"Tissue-resident memory t cells in skin diseases: A systematic review","volume":"22","author":"Emmanuel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3296","article-title":"Tissue-resident T cells in clinical response and immune-related adverse events of immune checkpoint blockade","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri2496","article-title":"Migration, maintenance and recall of memory T cells in peripheral tissues","volume":"9","author":"Woodland","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i35.6782","article-title":"Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors","volume":"12","author":"Maldonado-Garcia","year":"2024","journal-title":"World J Clin Cases"},{"key":"B15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12943-024-02166-w","article-title":"Cellular mechanisms of combining innate immunity activation with PD-1\/PD-L1 blockade in treatment of colorectal cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000383","article-title":"Immune checkpoint inhibitor-associated diarrhea and colitis: A systematic review and meta-analysis of observational studies","volume":"44","year":"2021","journal-title":"J immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:02:01Z","timestamp":1772607721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1760904"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760904","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1760904"}}